Psychotic disorders and comorbid substance use disorders: Clinical and therapeutic problems

被引:2
作者
Gouzoulis-Mayfrank E. [1 ]
机构
[1] LVR-Klinik Köln, Akademisches Lehrkrankenhaus der Universität zu Köln, Wilhelm-Griesinger Str. 23, Köln
关键词
Dual diagnosis; Integrative; Psychosis; Substance use disorders; Therapy;
D O I
10.1007/s11757-015-0352-1
中图分类号
学科分类号
摘要
Approximately half of the people with psychotic disorders from the schizophrenia group also develop a comorbid addictive disorder during their lifetime. These so-called dual diagnosis patients (DD) are difficult to treat. They have poor compliance and frequent relapses, they often present with aggressive behavior towards themselves and others and the long-term sociorehabilitative outcomes are poor. In this article the different models for the understanding of the high comorbidity between psychoses and substance use disorders are explained and the principles for an integrated treatment of DD patients are outlined. Low-threshold, motivational, integrated treatment programs with psychoeducative and behavioral therapeutic elements are helpful and should be more extensively implemented; however, long-term treatment methods are needed and therapeutic goals must be realistic and not set too high. © 2015, Springer-Verlag Berlin Heidelberg.
引用
收藏
页码:14 / 20
页数:6
相关论文
共 38 条
[31]  
Regier D.A., Farmer M.E., Rae D.S., Locke B.Z., Keith S.J., Judd L.L., Goodwin F.K., Comorbidity of mental disorders with alcohol and other drug abuse. Results from the Epidemiologic Catchment Area (ECA) Study, JAMA, 264, pp. 2511-2518, (1990)
[32]  
Rohdich R., Kirste A., Ein integrierter Behandlungsansatz für schizophrene Patienten mit Suchterkrankung und Persönlichkeitsstörung in der Klinik für Forensische Psychiatrie Haina, Recht Psychiatr, 23, pp. 116-122, (2005)
[33]  
Rubio G., Martinez I., Ponce G., Jimenez-Arriero M.A., Lopez-Munoz F., Alamo C., Long-acting injectable risperidone compared with zuclopenthixol in the treatment of schizophrenia with substance abuse comorbidity, Can J Psychiatry, 51, pp. 531-539, (2006)
[34]  
Sayers S.L., Campbell E.C., Kondrich J., Mann S.C., Cornish J., O'Brien C., Caroff S.N., Cocaine abuse in schizophrenic patients treated with olanzapine versus haloperidol, J Nerv Ment Dis, 193, pp. 379-386, (2005)
[35]  
Schnell T., Neisius K., Daumann J., Gouzoulis-Mayfrank E., Prävalenz der Komorbidität Psychose und Sucht – Klinisch-epidemiologische Ergebnisse aus einer deutschen Großstadt, Nervenarzt, 81, pp. 323-328, (2010)
[36]  
Schnell T., Koethe D., Krasnianski A., Gairing S., Schnell K., Daumann J., Gouzoulis-Mayfrank E., Ziprasidone vs. Clozapine in the treatment of dually diagnosed (DD) patients with schizophrenia and cannabis use disorders: a randomized study, Am J Addict, 23, pp. 308-312, (2014)
[37]  
Stuyt E.B., Sajbel T.A., Allen M.H., Differing effects of antipsychotic medications on substance abuse treatment patients with co-occurring psychotic and substance abuse disorders, Am J Addict, 15, pp. 166-173, (2006)
[38]  
Ziedonis D.M., D'Avanzo K., Schizophrenia and Substance abuse, Dual diagnosis and treatment, pp. 427-465, (1998)